Annual Operating Profit
-$135.22 M
+$105.01 M+43.71%
31 December 2023
Summary:
Nektar Therapeutics annual operaing income is currently -$135.22 million, with the most recent change of +$105.01 million (+43.71%) on 31 December 2023. During the last 3 years, it has risen by +$244.70 million (+64.41%). NKTR annual operating profit is now -119.66% below its all-time high of $687.93 million, reached on 31 December 2018.NKTR Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Operating Profit
-$34.30 M
+$2.19 M+5.99%
30 September 2024
Summary:
Nektar Therapeutics quarterly operating income is currently -$34.30 million, with the most recent change of +$2.19 million (+5.99%) on 30 September 2024. Over the past year, it has dropped by -$795.00 thousand (-2.37%). NKTR quarterly operating profit is now -103.52% below its all-time high of $973.60 million, reached on 30 June 2018.NKTR Quarterly Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Operating Profit
-$135.90 M
-$795.00 K-0.59%
30 September 2024
Summary:
Nektar Therapeutics TTM operating income is currently -$135.90 million, with the most recent change of -$795.00 thousand (-0.59%) on 30 September 2024. Over the past year, it has increased by +$9.56 million (+6.57%). NKTR TTM operating profit is now -114.33% below its all-time high of $948.29 million, reached on 30 June 2018.NKTR TTM Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NKTR Operating Profit Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +43.7% | -2.4% | +6.6% |
| 3 y3 years | +64.4% | +69.8% | +69.4% |
| 5 y5 years | -119.7% | +65.3% | +68.5% |
NKTR Operating Profit High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +69.7% | -11.9% | +70.2% | -2.4% | +69.9% |
| 5 y | 5 years | -119.7% | +69.7% | -11.9% | +70.2% | -2.4% | +69.9% |
| alltime | all time | -119.7% | +69.7% | -103.5% | +71.6% | -114.3% | +69.9% |
Nektar Therapeutics Operating Profit History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$34.30 M(-6.0%) | -$135.90 M(+0.6%) |
| June 2024 | - | -$36.48 M(+5.9%) | -$135.10 M(+1.8%) |
| Mar 2024 | - | -$34.45 M(+12.4%) | -$132.66 M(-1.9%) |
| Dec 2023 | -$135.22 M(-43.7%) | -$30.66 M(-8.5%) | -$135.22 M(-7.0%) |
| Sept 2023 | - | -$33.50 M(-1.6%) | -$145.45 M(-2.7%) |
| June 2023 | - | -$34.05 M(-8.0%) | -$149.42 M(-7.9%) |
| Mar 2023 | - | -$37.02 M(-9.5%) | -$162.17 M(-32.5%) |
| Dec 2022 | -$240.24 M(-46.1%) | -$40.89 M(+9.1%) | -$240.24 M(-23.1%) |
| Sept 2022 | - | -$37.47 M(-19.9%) | -$312.26 M(-19.6%) |
| June 2022 | - | -$46.79 M(-59.3%) | -$388.38 M(-14.0%) |
| Mar 2022 | - | -$115.08 M(+1.9%) | -$451.80 M(+1.3%) |
| Dec 2021 | -$446.10 M(+17.4%) | -$112.91 M(-0.6%) | -$446.10 M(+0.5%) |
| Sept 2021 | - | -$113.60 M(+3.1%) | -$443.91 M(+2.4%) |
| June 2021 | - | -$110.20 M(+0.7%) | -$433.37 M(+8.1%) |
| Mar 2021 | - | -$109.39 M(-1.2%) | -$400.87 M(+5.5%) |
| Dec 2020 | -$379.92 M(-13.7%) | -$110.72 M(+7.4%) | -$379.92 M(+0.3%) |
| Sept 2020 | - | -$103.05 M(+32.6%) | -$378.84 M(+1.2%) |
| June 2020 | - | -$77.71 M(-12.1%) | -$374.53 M(-8.2%) |
| Mar 2020 | - | -$88.44 M(-19.3%) | -$407.79 M(-7.3%) |
| Dec 2019 | -$440.04 M(-164.0%) | -$109.64 M(+11.0%) | -$440.04 M(+2.2%) |
| Sept 2019 | - | -$98.74 M(-11.0%) | -$430.69 M(+0.0%) |
| June 2019 | - | -$110.97 M(-8.1%) | -$430.59 M(-165.8%) |
| Mar 2019 | - | -$120.69 M(+20.3%) | $653.98 M(-4.9%) |
| Dec 2018 | $687.93 M(-1675.6%) | -$100.30 M(+1.7%) | $687.93 M(-11.8%) |
| Sept 2018 | - | -$98.63 M(-110.1%) | $780.17 M(-17.7%) |
| June 2018 | - | $973.60 M(-1222.4%) | $948.29 M(-1348.4%) |
| Mar 2018 | - | -$86.74 M(+977.1%) | -$75.96 M(+74.0%) |
| Dec 2017 | -$43.66 M(-61.3%) | -$8.05 M(-111.6%) | -$43.66 M(-35.6%) |
| Sept 2017 | - | $69.48 M(-237.2%) | -$67.75 M(-60.2%) |
| June 2017 | - | -$50.66 M(-6.9%) | -$170.14 M(+7.8%) |
| Mar 2017 | - | -$54.44 M(+69.4%) | -$157.81 M(+39.8%) |
| Dec 2016 | -$112.86 M(+284.2%) | -$32.14 M(-2.3%) | -$112.85 M(+2.5%) |
| Sept 2016 | - | -$32.90 M(-14.2%) | -$110.07 M(+43.4%) |
| June 2016 | - | -$38.33 M(+304.1%) | -$76.75 M(-6.3%) |
| Mar 2016 | - | -$9.48 M(-67.7%) | -$81.90 M(+178.8%) |
| Dec 2015 | -$29.37 M(+78.2%) | -$29.36 M(-7108.1%) | -$29.37 M(-21.7%) |
| Sept 2015 | - | $419.00 K(-101.0%) | -$37.49 M(-188.4%) |
| June 2015 | - | -$43.47 M(-201.0%) | $42.41 M(-32.6%) |
| Mar 2015 | - | $43.04 M(-214.8%) | $62.96 M(-481.9%) |
| Dec 2014 | -$16.48 M(-86.3%) | -$37.49 M(-146.7%) | -$16.48 M(+10.7%) |
| Sept 2014 | - | $80.32 M(-450.5%) | -$14.89 M(-85.4%) |
| June 2014 | - | -$22.92 M(-37.0%) | -$101.74 M(-8.7%) |
| Mar 2014 | - | -$36.40 M(+1.4%) | -$111.43 M(-7.2%) |
| Dec 2013 | -$120.13 M(-13.9%) | -$35.89 M(+450.1%) | -$120.13 M(-5.9%) |
| Sept 2013 | - | -$6.53 M(-80.0%) | -$127.61 M(-17.1%) |
| June 2013 | - | -$32.60 M(-27.7%) | -$153.99 M(+3.8%) |
| Mar 2013 | - | -$45.10 M(+4.0%) | -$148.37 M(+6.3%) |
| Dec 2012 | -$139.53 M(+12.6%) | -$43.38 M(+31.9%) | -$139.53 M(+6.8%) |
| Sept 2012 | - | -$32.90 M(+21.9%) | -$130.61 M(+9.7%) |
| June 2012 | - | -$26.99 M(-25.6%) | -$119.05 M(-5.8%) |
| Mar 2012 | - | -$36.26 M(+5.2%) | -$126.33 M(+1.9%) |
| Dec 2011 | -$123.94 M(+690.5%) | -$34.47 M(+61.5%) | -$123.94 M(+27.2%) |
| Sept 2011 | - | -$21.34 M(-37.7%) | -$97.43 M(+18.4%) |
| June 2011 | - | -$34.26 M(+1.2%) | -$82.32 M(+78.2%) |
| Mar 2011 | - | -$33.87 M(+325.3%) | -$46.19 M(+194.6%) |
| Dec 2010 | -$15.68 M(-83.5%) | -$7.96 M(+27.9%) | -$15.68 M(+18.7%) |
| Sept 2010 | - | -$6.22 M(-433.4%) | -$13.21 M(-63.1%) |
| June 2010 | - | $1.87 M(-155.6%) | -$35.84 M(-47.4%) |
| Mar 2010 | - | -$3.36 M(-38.9%) | -$68.19 M(-28.3%) |
| Dec 2009 | -$95.13 M | -$5.50 M(-81.0%) | -$95.13 M(+55.9%) |
| Sept 2009 | - | -$28.86 M(-5.3%) | -$61.02 M(-8.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2009 | - | -$30.48 M(+0.6%) | -$66.72 M(-4.1%) |
| Mar 2009 | - | -$30.30 M(-205.9%) | -$69.60 M(-14.3%) |
| Dec 2008 | -$81.19 M(+124.6%) | $28.61 M(-182.8%) | -$81.19 M(+12.1%) |
| Sept 2008 | - | -$34.56 M(+3.6%) | -$72.43 M(+26.1%) |
| June 2008 | - | -$33.36 M(-20.4%) | -$57.44 M(+10.3%) |
| Mar 2008 | - | -$41.89 M(-212.1%) | -$52.07 M(+44.0%) |
| Dec 2007 | -$36.15 M(-77.3%) | $37.38 M(-291.0%) | -$36.15 M(-68.2%) |
| Sept 2007 | - | -$19.57 M(-30.1%) | -$113.69 M(-2.7%) |
| June 2007 | - | -$27.99 M(+7.8%) | -$116.80 M(-23.2%) |
| Mar 2007 | - | -$25.97 M(-35.3%) | -$152.03 M(-4.5%) |
| Dec 2006 | -$159.23 M(-8.9%) | -$40.16 M(+77.1%) | -$159.23 M(-27.6%) |
| Sept 2006 | - | -$22.68 M(-64.1%) | -$219.93 M(-0.3%) |
| June 2006 | - | -$63.21 M(+90.5%) | -$220.62 M(+20.0%) |
| Mar 2006 | - | -$33.17 M(-67.1%) | -$183.86 M(+5.2%) |
| Dec 2005 | -$174.77 M(+136.4%) | -$100.86 M(+331.7%) | -$174.77 M(+89.3%) |
| Sept 2005 | - | -$23.37 M(-11.7%) | -$92.31 M(+5.2%) |
| June 2005 | - | -$26.45 M(+9.8%) | -$87.77 M(+6.5%) |
| Mar 2005 | - | -$24.09 M(+30.9%) | -$82.44 M(+11.2%) |
| Dec 2004 | -$73.94 M(+11.7%) | -$18.40 M(-2.3%) | -$74.15 M(-2.0%) |
| Sept 2004 | - | -$18.83 M(-10.8%) | -$75.66 M(+6.6%) |
| June 2004 | - | -$21.12 M(+33.6%) | -$70.97 M(+10.1%) |
| Mar 2004 | - | -$15.81 M(-20.6%) | -$64.45 M(-2.6%) |
| Dec 2003 | -$66.19 M(-33.9%) | -$19.91 M(+40.9%) | -$66.19 M(-12.4%) |
| Sept 2003 | - | -$14.13 M(-3.2%) | -$75.52 M(-12.2%) |
| June 2003 | - | -$14.60 M(-16.7%) | -$85.97 M(-8.6%) |
| Mar 2003 | - | -$17.54 M(-40.0%) | -$94.04 M(-6.0%) |
| Dec 2002 | -$100.08 M(-9.6%) | -$29.24 M(+19.0%) | -$100.08 M(-3.4%) |
| Sept 2002 | - | -$24.58 M(+8.4%) | -$103.64 M(-3.6%) |
| June 2002 | - | -$22.68 M(-3.8%) | -$107.55 M(-3.1%) |
| Mar 2002 | - | -$23.58 M(-28.1%) | -$111.01 M(+0.3%) |
| Dec 2001 | -$110.70 M(+73.4%) | -$32.80 M(+15.1%) | -$110.70 M(+15.6%) |
| Sept 2001 | - | -$28.49 M(+9.0%) | -$95.73 M(+15.1%) |
| June 2001 | - | -$26.14 M(+12.3%) | -$83.18 M(+15.0%) |
| Mar 2001 | - | -$23.27 M(+30.5%) | -$72.35 M(+13.3%) |
| Dec 2000 | -$63.85 M(+108.7%) | -$17.84 M(+11.9%) | -$63.85 M(+13.8%) |
| Sept 2000 | - | -$15.94 M(+4.2%) | -$56.09 M(+17.3%) |
| June 2000 | - | -$15.30 M(+3.6%) | -$47.82 M(+22.2%) |
| Mar 2000 | - | -$14.77 M(+46.6%) | -$39.12 M(+28.1%) |
| Dec 1999 | -$30.59 M(+39.1%) | -$10.08 M(+31.4%) | -$30.55 M(+12.1%) |
| Sept 1999 | - | -$7.67 M(+16.2%) | -$27.26 M(+7.4%) |
| June 1999 | - | -$6.60 M(+6.5%) | -$25.39 M(+11.5%) |
| Mar 1999 | - | -$6.20 M(-8.7%) | -$22.78 M(+4.2%) |
| Dec 1998 | -$21.99 M(+60.2%) | -$6.79 M(+17.1%) | -$21.86 M(+12.9%) |
| Sept 1998 | - | -$5.80 M(+45.3%) | -$19.37 M(+13.7%) |
| June 1998 | - | -$3.99 M(-24.4%) | -$17.03 M(+4.9%) |
| Mar 1998 | - | -$5.28 M(+22.7%) | -$16.23 M(+18.5%) |
| Dec 1997 | -$13.72 M(+19.3%) | -$4.30 M(+24.1%) | -$13.69 M(+3.8%) |
| Sept 1997 | - | -$3.46 M(+8.6%) | -$13.20 M(+6.1%) |
| June 1997 | - | -$3.19 M(+16.2%) | -$12.43 M(+1.5%) |
| Mar 1997 | - | -$2.74 M(-27.8%) | -$12.24 M(+5.6%) |
| Dec 1996 | -$11.50 M(+30.7%) | -$3.80 M(+40.7%) | -$11.60 M(+12.6%) |
| Sept 1996 | - | -$2.70 M(-10.0%) | -$10.30 M(+7.3%) |
| June 1996 | - | -$3.00 M(+42.9%) | -$9.60 M(+11.6%) |
| Mar 1996 | - | -$2.10 M(-16.0%) | -$8.60 M(-2.3%) |
| Dec 1995 | -$8.80 M(+54.4%) | -$2.50 M(+25.0%) | -$8.80 M(+1.1%) |
| Sept 1995 | - | -$2.00 M(0.0%) | -$8.70 M(+11.5%) |
| June 1995 | - | -$2.00 M(-13.0%) | -$7.80 M(+13.0%) |
| Mar 1995 | - | -$2.30 M(-4.2%) | -$6.90 M(+23.2%) |
| Dec 1994 | -$5.70 M | -$2.40 M(+118.2%) | -$5.60 M(+75.0%) |
| Sept 1994 | - | -$1.10 M(0.0%) | -$3.20 M(+52.4%) |
| June 1994 | - | -$1.10 M(+10.0%) | -$2.10 M(+110.0%) |
| Mar 1994 | - | -$1.00 M | -$1.00 M |
FAQ
- What is Nektar Therapeutics annual operaing income?
- What is the all time high annual operating profit for Nektar Therapeutics?
- What is Nektar Therapeutics annual operating profit year-on-year change?
- What is Nektar Therapeutics quarterly operating income?
- What is the all time high quarterly operating profit for Nektar Therapeutics?
- What is Nektar Therapeutics quarterly operating profit year-on-year change?
- What is Nektar Therapeutics TTM operating income?
- What is the all time high TTM operating profit for Nektar Therapeutics?
- What is Nektar Therapeutics TTM operating profit year-on-year change?
What is Nektar Therapeutics annual operaing income?
The current annual operating profit of NKTR is -$135.22 M
What is the all time high annual operating profit for Nektar Therapeutics?
Nektar Therapeutics all-time high annual operaing income is $687.93 M
What is Nektar Therapeutics annual operating profit year-on-year change?
Over the past year, NKTR annual operaing income has changed by +$105.01 M (+43.71%)
What is Nektar Therapeutics quarterly operating income?
The current quarterly operating profit of NKTR is -$34.30 M
What is the all time high quarterly operating profit for Nektar Therapeutics?
Nektar Therapeutics all-time high quarterly operating income is $973.60 M
What is Nektar Therapeutics quarterly operating profit year-on-year change?
Over the past year, NKTR quarterly operating income has changed by -$795.00 K (-2.37%)
What is Nektar Therapeutics TTM operating income?
The current TTM operating profit of NKTR is -$135.90 M
What is the all time high TTM operating profit for Nektar Therapeutics?
Nektar Therapeutics all-time high TTM operating income is $948.29 M
What is Nektar Therapeutics TTM operating profit year-on-year change?
Over the past year, NKTR TTM operating income has changed by +$9.56 M (+6.57%)